

1 **Title: Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care**
2 **Testing**

3 **Running Title –Validation of SARS-CoV-2 POCT**

4
5 **Authors:** Steven E. Conklin^{*a} Kathryn Martin^{*a}, Yukari C Manabe^b, Haley A Schmidt^a, Jernelle
6 Miller^a, Morgan Keruly^c, Ethan Klock^b, Charles S Kirby^a, Owen R Baker^c, Reinaldo E
7 Fernandez^b, Yolanda J Eby^a, Justin Hardick^b, Kathryn Shaw-Saliba^d, Richard E Rothman^d,
8 Patrizio P Caturegli^a, Andrew R Redd^{b,c}, Aaron AR Tobian^{a,b}, Evan M Bloch^a, H Benjamin
9 Larman^a, Thomas C Quinn^{b,c}, William Clarke^{#a} and Oliver Laeyendecker^{#b,c}

10 * These authors contributed equally to this manuscript

11 # These authors contributed equally to this manuscript

12
13 **Affiliations:**

14 a) Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore,
15 Maryland, USA

16 b) Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore
17 Maryland, USA

18 c) Division of Intramural Research, National Institute of Allergy and Infectious Diseases,
19 National Institutes of Health, Baltimore, Maryland, USA.

20 d) Department of Emergency Medicine, Johns Hopkins University School of Medicine,
21 Baltimore, Maryland, USA

22
23 **Keyword:** SARS-CoV-2 serology; point of care test; performance; cross-reactivity

24
25 **Corresponding author:**

26 Oliver Laeyendecker MS, MBA, PhD
27 855 North Wolfe St.
28 Rangos Building, room 538A
29 Baltimore MD, 21205
30 Phone: 410-502-3268
31 Email: olaeyen1@jhmi.edu
32
33
34

35 **ABSTRACT**

36 **Background.** Rapid point-of-care tests (POCTs) for SARS-CoV-2-specific antibodies vary in
37 performance. A critical need exists to perform head-to-head comparison of these assays.

38 **Methods.** Performance of fifteen different lateral flow POCTs for the detection of SARS-CoV-
39 2-specific antibodies was performed on a well characterized set of 100 samples. Of these, 40
40 samples from known SARS-CoV-2-infected, convalescent individuals (average of 45 days post
41 symptom onset) were used to assess sensitivity. Sixty samples from the pre-pandemic era
42 (negative control), that were known to have been infected with other respiratory viruses
43 (rhinoviruses A, B, C and/or coronavirus 229E, HKU1, NL63 OC43) were used to assess
44 specificity. The timing of seroconversion was assessed on five POCTs on a panel of 272
45 longitudinal samples from 47 patients of known time since symptom onset.

46 **Results.** For the assays that were evaluated, the sensitivity and specificity for any reactive band
47 ranged from 55%-97% and 78%-100%, respectively. When assessing the performance of the
48 IgM and the IgG bands alone, sensitivity and specificity ranged from 0%-88% and 80%-100%
49 for IgM and 25%-95% and 90%-100% for IgG. Longitudinal testing revealed that median time
50 post symptom onset to a positive result was 7 days (IQR 5.4, 9.8) for IgM and 8.2 days (IQR 6.3
51 to 11.3).

52 **Conclusion.** The testing performance varied widely among POCTs with most variation related to
53 the sensitivity of the assays. The IgM band was most likely to misclassify pre-pandemic
54 samples. The appearance of IgM and IgG bands occurred almost simultaneously.

55

56 **Introduction**

57 The respiratory illness Coronavirus disease-19 (COVID-19) is caused by severe acute
58 respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection.[1] The COVID-19 pandemic
59 has challenged the diagnostic testing capacity of the global healthcare industry. Though the
60 initial burden of disease was most pronounced in high-income countries, the pandemic has since
61 spread to middle- and low-income countries that lack substantial laboratory infrastructure.
62 Despite major efforts to contain and slow down the viral spread, the limited testing capability of
63 hospitals, public health laboratories, and government agencies remains a major challenge.
64 Accurate serological tests for SARS-CoV-2 infection are used to estimate the numbers of
65 individuals who have been infected and have developed a humoral immune response
66 (seroconvert). Understanding seroprevalence is important to determine the spread of the disease
67 and to identify populations with a high burden of infection.[2] Furthermore, if previous infection
68 provides immunity to the disease, these assays could be used to determine those who would be
69 vulnerable or protected from infection.

70 Broadly, there are two types of assay formats to detect antibodies against SARS-CoV-2
71 infection enzyme-linked immunosorbent assays (ELISAs) and serologic lateral flow assays
72 (LFA). ELISAs, with or without a chemiluminescent signal, offer high throughput testing, but
73 require substantial laboratory infrastructure and trained personnel for operation.[3] LFAs that
74 detect antibodies against SARS-CoV-2 are easy to use, rapid, portable and often qualify as point
75 of care tests (POCT) that can be used outside of a centralized laboratory facility. [4] POCT can
76 be used at home or in a doctor's office and take minutes to complete. Unfortunately there is a
77 great deal of variation on the performance of these POCT assays for the accurate detection of
78 antibodies to SARS-CoV-2 infection.[5] Serologic LFAs can have wide ranging performance

79 based on the viral antigens used and how they were elaborated, and the construction of the
80 cassette.

81 Lack of standardization makes performance comparison of serological assays
82 challenging. Structurally, SARS-CoV-2 possesses four main structural proteins: spike
83 glycoprotein (S), envelope glycoprotein (E), membrane glycoprotein (M), and nucleocapsid
84 protein (N).[6,7] These proteins are immunogens capable of inducing the generation of the IgA,
85 IgG, and/or IgM antibodies targeted by LFAs. Unstandardized iterations in the antigen/antibody
86 combination used by LFAs is a key contributor for performance variation among platforms. Poor
87 understanding of immunological response kinetics to SARS-CoV-2 infection further complicates
88 evaluation. The impact of these variables was evident upon initiating comparison of different
89 LFAs for SARS-CoV-2 antibody detection. [8–11] Initial reports are mixed: some report LFAs
90 as being unsuitable for use, while others profess their potential for rapid screening of patients for
91 acute infection.[9–11] Many of these studies were constrained by small sample sizes, failure to
92 evaluate for cross-reactivity and failure to assess sensitivity of the assays by stage of infection,
93 all of which could influence the findings.

94 Many LFAs were released into the market quickly due to US Food and Drug
95 Administration (FDA) emergency use authorization (EUA) as a response to the COVID-19
96 pandemic without a comprehensive assessment of performance. Since then, stricter criteria for
97 approval have been in place due to greater US FDA oversight of the antibody testing EUA
98 process. [12] These include evaluation of cross-reactivity (specificity >95% to other
99 coronaviruses), specificity approaching 100%, high positive/negative predictive agreement
100 ($\geq 90\%$). Regardless of EUA approval, assessing the performance characteristics of LFAs is

101 necessary for understanding the longitudinal thresholds for sensitivity and specificity, and
102 potential cross-reactivity with other non-SARS-CoV-2 viruses.

103 For SARS-CoV-2, antibody reactivity or presence is generally measured as time from
104 symptom onset.[13] While consensus on the optimal time to perform the POCT is lacking, the
105 majority of reports suggest that the tests are best undertaken >14 days post-symptom onset.[14–
106 19] Furthermore, studies on samples from convalescent plasma donors, who had a documented
107 positive RT-PCR test, demonstrate that some individuals have undetectable antibody
108 responses.[20] In terms of specificity, false positive results may occur for a variety of reasons,
109 particularly due to cross reactivity to other coronaviruses (229E, HKU1, NL63, and
110 OC43).[9,12-22]

111 Despite increasing reports on the performance of individual POCTs to detect SARS-
112 CoV-2 antibodies, the overall performance of all the commercially available POCTs is still
113 unclear. To further expand POCT evaluation, we compared the performance of multiple POCTs
114 for SARS-CoV-2 antibody detection. To this end we used the same set of samples from known
115 infected and uninfected individuals to perform a head-to-head analysis of 15 POCT assays. We
116 further evaluated seven of these assays to assess the time window between onset of symptoms
117 and detection of antibodies to SARS-CoV-2 infection. Overall, the goal of our work is
118 highlighting the performance characteristics of a series of LFAs to further expand general
119 understanding of LFA utility and serve as an informative reference for potential deployment
120 efforts.

121

122 **Materials and Methods**

123 **Characteristics of Individuals Studied**

124 *Ethics statement:* The parent studies were approved by The Johns Hopkins University School of
125 Medicine Institutional Review Board (IRB00247886, IRB00250798 and IRB00091667). All
126 samples were de-identified prior to testing. The parent studies were conducted according to the
127 ethical standards of the Helsinki Declaration of the World Medical Association. This report
128 includes an analysis of stored samples and data from those studies. No additional samples were
129 collected for the current study.

130 *Convalescent SARS-CoV-2 samples:* The sensitivity of the POCTs was performed on 40 samples
131 from convalescent plasma donors.[22] These individuals had to have been RT-PCR positive for
132 SARS-CoV-2, and asymptomatic for at least 28 days. The time interval between date of
133 symptom onset and the sample drawn for this study was 45 days (SD \pm 7.5 days). All subjects
134 were HIV and HCV negative. (**Table 1** and **Table S1**).

135

136 *Pre Pandemic challenge samples:* Specificity of assays was assessed with 60 samples from pre-
137 pandemic timepoints of individuals known to be uninfected by SARS-CoV-2. These samples
138 came from a study of patients presenting to the Johns Hopkins Hospital Emergency Department
139 with symptoms of an acute respiratory tract infection between 2016-20 as part of the Johns
140 Hopkins Center for Influenza Research and Surveillance study.[26] At the time of illness
141 nasopharyngeal swabs and sera were obtained at the same time. Nasopharyngeal swabs were
142 tested for influenza A/B viruses utilizing the Cepheid GeneXpert Xpress Flu A/B/RSV assay
143 (Cepheid, Sunnyvale, CA), and were subsequently tested for respiratory viral and bacterial co-
144 infections as well as non-influenza respiratory viruses and bacterial pathogens utilizing the

145 Genmark ePlex RP RUO cartridges (Genmark, Carlsbad, CA). The sera from these time points
146 was tested with the VirScan assay, as previously described,[27,28] to identify samples with IgG
147 reactivity to other coronaviruses. For the analysis performed in this paper only data related to
148 coronaviruses 229E, HKU1, NL63 and OC43 was analyzed. Any sample that was reactive to any
149 peptide for these viruses was considered to have antibodies present against these viruses (**Table**
150 **1, Table S1 and Fig. S1**).

151 Longitudinal study samples: To determine the sensitivity of antibody testing by duration of
152 infection, plasma specimens obtained from individuals with known date of symptom onset who
153 had serial specimens were tested. Samples (n=272) came from 47 hospitalized SARS-CoV-2
154 RT-PCR confirmed patients and were used to determine the sensitivity by duration of infection
155 for a subset SARS-CoV-2 point of care antibody test kits evaluated. (**Table 1**).

156

157 **Serology testing for antibodies to SARS-CoV-2 infection**

158 All POCTs were performed according to the manufacturers' protocol. (**Table S2**). Any
159 detectable band was considered a positive result. Results were considered invalid when the
160 control band was not visible (**Figure 1**). Samples were also tested using the Euroimmun Anti-
161 SARS-CoV-2 ELISA (Mountain Lakes, NJ) with values e and the Epitope Diagnostic IgM
162 ELISA (San Diego, CA) per manufacturer's protocol. The ELISA data served as a control.

163

164 **Analysis**

165 Sensitivity: This calculation was performed for both the samples from convalescent individuals
166 (n=40) and the longitudinally followed individuals. For the longitudinal samples, sensitivity was
167 calculated at four different time intervals, 0-5, 6-10, 11-15, and 16-20 days post symptom onset.
168 Sensitivity was calculated for IgM and IgG separately, and for IgM or IgG using the following
169 equation:

170
$$\text{Sensitivity (\%)} = 100 \times [\text{Positive} / (\text{Positive} + \text{False Negative})].$$

171 Specificity: This calculation was performed for the pre-pandemic sample set (n=60). The impact
172 of sero-reactivity to other coronaviruses was assessed. Specificity was calculated for IgM and
173 IgG separately, and for IgM or IgG using the following equation:

174
$$\text{Specificity (\%)} = 100 \times [\text{Negative} / (\text{Negative} + \text{False Positive})].$$

175 Percent Agreement: This calculation was performed with the samples from both the convalescent
176 samples and the pre-pandemic era samples. The following equation was used to calculate the
177 percent agreement:

178
$$\text{Agreement (\%)} = 100 \times (n \text{ agree} / \text{total } n)$$

179 **Results**

180 **Sensitivity and specificity of IgM and IgG vary by SARS-CoV-2 antibody-based assays.**
181 Performance results varied across the different assays (**Figure 2**). Considering the detection of
182 IgM, IgG, or either as a positive result, sensitivity of the assays ranged from 55% (95% CI 38-
183 71%) to 97% (95% CI 87-100%) and specificity from 80% (95% CI 67-89%) to 100% (95% CI
184 97-100%). Of the assays tested, Premier Biotech and Clarity exhibited the highest sensitivity

185 (97%; 95% CI 87-100%), while for specificity, CoronaChek, Premier Biotech and Sensing Self
186 were the best performers (100%; 95% CI 94-100%). Lowest sensitivity was obtained from
187 Wondfo (55%; 95% CI 38-71%), followed by Zeus (57.5%; 95% CI 41-73%), while the lowest
188 specificity was obtained from DNA Link (80%; 95% CI 67.2-89.0%) and Nirmidas (85%; 95%
189 CI 73-93%). In general the IgM band had a lower sensitivity among the samples from
190 convalescent individuals (0% to 87.5%) compared to the IgG band (25.0% to 95.0%). Only for
191 the Clarity and Smart Screen assay was sensitivity reversed. Overall, the specificity was much
192 lower for the IgM band than the IgG band ($p < 0.05$).

193 Of the fifteen assays evaluated, CoronaChek, Premier Biotech, and Sensing Self were the
194 only tests without false-positive results when testing the designated negative SARS-CoV-2
195 samples (**Figure 3a**). Fourteen out of sixty samples generated false-positive results on more than
196 one POCT assay. Most of the specimens that generated a false-positive result, did so in four
197 different tests. Similarly, false-negative results were obtained when testing samples from patients
198 known to be RT-PCR positive. Twenty-eight out of forty samples generated a false-negative
199 result on more than one POCT. Of note, one specimen generated a false-negative result for all
200 but two of the tests.

201
202 **Crossreactivity with other viral infections.** To further evaluate the specificity of the different
203 assays, a set of challenge specimens were tested. These specimens comprised pre-pandemic
204 samples obtained between 2016 and 2019 from patients known to be infected with other non-
205 SARS-CoV-2 viruses. False-positive results were obtained with all the viral-specific antibodies
206 tested (**Fig. S1**). Crossreactivity was more pronounced with sera from patients infected with

207 different strains of coronaviruses (229E, HKU1, NL63, and OC43); little cross-reactivity was
208 observed from sera from patients known to have influenza A, B, or C and parainfluenza.

209

210 **Agreement between assays.** Agreement among the evaluated POCTs ranged from 53% to 100%
211 (**Figure 3b**). The majority of the assays' results agreed between 75% and 100%, but four assays
212 (Covisure, Smart Screen, Wondfo, and Zeus) had lower agreement (53% to 82%). Lowest
213 agreement was obtained between Wondfo and Ready Result (53%), while the highest percent
214 agreement was obtained between Premier Biotech and Clarity (100%), All Test and Safe Care
215 (98%), Safe Care and Clarity (98%), CoronaChek and Clarity (98%), and TBG with DNA Link
216 (98%). IgM results had lower percent agreement than those for IgG results (**Fig. S2a and S2b**).

217 Two ELISA-based tests, EDI IgM and the Euroimmun IgG, were used as a comparison to the
218 POCT-based assays (**Figure 3a**). The EDI IgM ELISA had thirty-five negative results out of the
219 40 convalescent plasma samples tested. Euroimmun ELISA testing resulted in one false-negative
220 result (sample 39), which was IgG negative by all POCTs evaluated. Both ELISAs generated one
221 false-positive result when testing the pre-pandemic samples (negative control), and both of these
222 were obtained for different samples. When evaluating the percent agreement between the POCTs
223 and ELISAs (**Figure 3b**), the percent agreement ranged from 13%-54% and 13%-100% for EDI
224 and Euroimmun, respectively.

225 Comparison of IgM and IgG ELISA values with the POCT results provided further insight on
226 each POCTs performance. EDI IgM ELISA ODn values between positive and negative POCT
227 results had little variation (**Fig. S3**), which underscores the poor agreement between EDI and the
228 POCTs. Euroimmun IgG S/C values had a stronger correlation with POCT results (**Fig. S4**).

229 However, for a subset of assays, samples with high positive ELISA values had a negative POCT
230 result, suggesting POCT false-negative results.

231

232 **Sensitivity by duration of infection.** The sensitivity of IgM, IgG or any reactivity increased
233 with duration of infection. The performance of five POCTs (CoronaChek, DNA Link, Nirmidas,
234 Sensing Self, and TBG) and three ELISAs (Euroimmun, and both the IgM and IgG by EDI) was
235 evaluated using longitudinal samples from 47 hospitalized patients from day 0 to day 20 post-
236 onset of symptoms. The sensitivity for both IgM and IgG increased over time up to 20 days post-
237 symptom onset (**Figure 4**). The median time to sero-reactivity shorter for IgM was 7 days
238 (interquartile range [IQR] 5.4, 9.8) and 8.2 days (IQR 6.3, 11.3) for IgG. However, it was not
239 always true that IgM band appeared before the IgG band. For 13 patients the IgG bands
240 appeared earlier or on the same date as the IgM bands. For two of these patients, only IgG was
241 detected regardless of the time of testing. Four others did not obtain a positive result either by
242 POCT or ELISA for the time points evaluated.

243

244 **Discussion**

245 POCTs for SARS-CoV-2 antibody testing are appealing given their low cost, ease of
246 distribution, and clinical use. However, the performance and reliability of these tests to detect
247 IgM and IgG against SARS-CoV-2 at different stages of COVID-19 remain unclear, and
248 information about cross-reactivity of these assays towards other viral antibodies is lacking. It is
249 unknown if this is a problem with the antigen being used or the formulation of the assay itself.
250 Using 15 commercially available POCTs, we demonstrate variation in test performance of these

251 assays as well as cross-reactivity with other viral antibodies. Using longitudinal samples from
252 patients with documented COVID-19, the findings indicate optimal sensitivity approximately
253 three weeks following onset of symptoms.

254 The panel of POCTs evaluated had a combined sensitivity and specificity for IgM and IgG
255 between 55%-97% and 80%-100%, respectively. AllTest, Premier Biotech and Wondfo have
256 been previously evaluated.[21,25,29–31] Our performance results are similar to these previously
257 reported values, except for Wondfo, which had a lower sensitivity and specificity [55% (95% CI
258 38%-71%) and 96% (95% CI 91%-100%), respectively]. It is unclear as to why the values
259 differed.

260 Of the tests evaluated, only the CoronaChek, Premier Biotech, and Sensing Self assays did
261 not generate a false positive response on our panel of 60 samples from individuals known to have
262 been infected with other respiratory infections. Our data demonstrated that samples from patients
263 infected with other coronaviruses (229E, HKU1, NL63, and OC43) are more prone to cross-
264 reactivity than those infected with influenza A, B, or C, parainfluenza, HIV, rhinovirus and
265 enterovirus. Cross-reactivity with other viral antibodies has been reported for other SARS-CoV-
266 2-specific IgM and IgG antibody immunoassays.[21,25] Whitman and coworkers performed
267 cross-reactivity controls with 10 POCTs by testing samples from individuals that tested negative
268 for SARS-CoV-2 and/or had other viral and inflammatory illnesses.[21] The evaluated POCTs
269 were prone to cross-react against viruses other than SARS-CoV-2, but no consistent pattern was
270 identified.

271 The immunologic response to SARS-CoV-2 infection begins as early as a couple of days
272 after symptom onset. In our cohort of symptomatic, hospitalized patients diagnosed with
273 COVID-19, seroconversion occurred in 64% of individuals by 14 days, similar to previous

274 investigations.[13,24,32–34] After seroconversion, IgM levels have been shown to decline and
275 are almost undetectable by the seventh week post-onset symptoms, while IgG levels persist past
276 the seventh week.[13,35] In our study, we also observed an increase in IgM and IgG detection in
277 the first two weeks post-onset of symptoms, and less seroreactivity to IgM among convalescent
278 plasma donors whose samples were tested approximately a month and a half after symptom
279 onset. We did observe a sample from a convalescent donor that was IgG negative for all assays
280 evaluated (15 POCTs and Euroimmun ELISA), highlighting that not all infected individuals
281 generate detectable antibody responses.

282 The limitations to our study included the lack of early infection samples from non-
283 hospitalized patients. Additionally, specificity analysis needs to be performed on hundreds if not
284 thousands of samples to determine factors associated with misclassification and to give better
285 precision of the point estimate. Furthermore, the samples evaluated were from the Baltimore-
286 Washington region of the United States and may not reflect performance of these assays in
287 different parts of the world. Future studies should include samples from different regions of the
288 world, where the underlying host genetics and common viral infections vary to determine the
289 robustness of POCT performance. Additionally, studies using testing algorithms applying
290 different assays in combination, which test different target antigens of the virus should be
291 evaluated, as such methodology has proven highly effective for testing other infections such as
292 HIV.

293 The current “gold standard” test for the diagnosis of COVID-19 is RT-PCR. RT-PCR has
294 disadvantages, including cost, lengthy turn-around-times, and preanalytical variability.
295 Additionally, the sensitivity of this method declines past the first week after onset of
296 symptoms.[33,36] POCTs could be used in parallel with RT-PCR testing as a supplemental

297 diagnostic tool in patients suspected to have infection who are RT-PCR negative who are more
298 than 14 days from onset of symptoms. Serologic assays also facilitate population level
299 monitoring of COVID-19 exposure. Of note, POCTs should be considered supplemental
300 diagnostic tools, not confirmatory tests.

301 Overall, antibody-based testing shows great promise as an easy and rapid screening method
302 for determining SARS-CoV-2 exposure. However, comprehensive evaluation of these tests
303 should be performed prior to their clinical implementation. If antibodies to SARS-CoV-2 do
304 provide long-term immunological protection, then POCTs could play a pivotal role in the
305 evaluation of protective immunity. In summary, our study provides insight into the performance
306 of a series of POCTs and some of the factors capable of influencing their performance. With
307 appropriate use, these tests have the potential to broaden the reach of testing, and maximize the
308 detection of asymptomatic infected individuals.

309

310 **Acknowledgments**

311 We are grateful for all of the study participants who donated plasma, the clinical staff, including Sonali
312 Thapa and Liz Martinez, Mary De'Jarnette, Carlos Aguado, Peggy Iraola, Jackie Lobien who collected
313 samples.

314

315 **Financial support:**

316 The study was supported by the Division of Intramural Research, National Institute of Allergy and
317 Infectious Diseases (NIAID), National Institutes of Health (NIH). Research reported in this publication
318 was supported research awards: NIAID, [UM1-AI068613 R01AI120938 and R01AI128779]; National
319 Institute of Biomedical Imaging and Bioengineering [U54EB007958]; National Heart, Lung, and Blood

320 Institute of the National Institutes of Health [K23HL151826 and 1K23HL151826-01]. Work was
321 supported in part by the NIAID Contract HHSN272201400007C awarded to the Johns Hopkins Center
322 for Influenza Research and Surveillance (JHCEIRS).

323

324 **Conflicts of Interest:**

325 EMB is a member of the United States Food and Drug Administration (FDA) Blood Products Advisory
326 Committee. Any views or opinions that are expressed in this manuscript are that of the author's, based on
327 his own scientific expertise and professional judgment; they do not necessarily represent the views of
328 either the Blood Products Advisory Committee or the formal position of FDA, and also do not bind or
329 otherwise obligate or commit either Advisory Committee or the Agency to the views expressed.

330

331 **References:**

- 332 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in
333 China, 2019. *N Engl J Med* **2020**; 382:727–733.
- 334 2. Gronvall G, Connel N, Kobokovich A, et al. Developing a National Strategy for Serology
335 (Antibody Testing) in the United States. 2020.
- 336 3. Clarke W, Sokoll LJ, Rai AJ. Chapter 12 - Immunoassays. In: Clarke W, Marzinke
337 MABT-CP in CC (Fourth E, eds. . Academic Press, 2020: 201–214. Available at:
338 <http://www.sciencedirect.com/science/article/pii/B9780128154991000120>.
- 339 4. Koczula KM, Gallotta A. Lateral flow assays. *Essays Biochem* **2016**; 60:111–120.
- 340 5. Joseph A, Branswell H. The results of coronavirus ‘serosurveys’ are starting to be

- 341 released. Here's how to kick their tires. 2020. Available at:
342 [https://www.statnews.com/2020/04/24/the-results-of-coronavirus-serosurveys-are-](https://www.statnews.com/2020/04/24/the-results-of-coronavirus-serosurveys-are-starting-to-be-released-heres-how-to-kick-their-tires/)
343 [starting-to-be-released-heres-how-to-kick-their-tires/](https://www.statnews.com/2020/04/24/the-results-of-coronavirus-serosurveys-are-starting-to-be-released-heres-how-to-kick-their-tires/). Accessed 6 April 2020.
- 344 6. Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An
345 overview of viral structure and host response. *Diabetes Metab Syndr Clin Res Rev* **2020**;
346 14:407–412. Available at:
347 <http://www.sciencedirect.com/science/article/pii/S1871402120300849>.
- 348 7. Wang Q, Zhang Y, Wu L, et al. Structural and Functional Basis of SARS-CoV-2 Entry by
349 Using Human ACE2. *Cell* **2020**; 181:894-904.e9.
- 350 8. U.S. Food and Drug Administration. Independent Evaluations of COVID-19 Serological
351 Tests. Available at: <https://open.fda.gov/apis/device/covid19serology/>. Accessed 6 July
352 2020.
- 353 9. Li Z, Yi Y, Luo X, et al. Development and Clinical Application of A Rapid IgM□IgG
354 Combined Antibody Test for SARS□CoV□2 Infection Diagnosis. *J Med Virol* **2020**;
- 355 10. Barna V, Katalin K, Eszter O, Dóra S, Zoltán P, Béla M. The diagnostic value of rapid
356 anti IgM and IgG detecting tests in the identification of patients with SARS CoV-2 virus
357 infection. *Orv Hetil* **2020**; 161:807–812.
- 358 11. Cassaniti I, Novazzi F, Giardina F, et al. Performance of VivaDiag COVID-19 IgM/IgG
359 Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to
360 emergency room department. *J Med Virol* **2020**; :1–4.
- 361 12. National Center for Immunization and Respiratory Diseases (NCIRD) D of VD. Interim

- 362 Guidelines for COVID-19 Antibody Testing. Available at:
363 <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html>.
364 Accessed 6 July 2020.
- 365 13. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with
366 COVID-19. *Nat Med* **2020**; :1–4. Available at: [http://www.nature.com/articles/s41591-](http://www.nature.com/articles/s41591-020-0897-1)
367 [020-0897-1](http://www.nature.com/articles/s41591-020-0897-1).
- 368 14. Montesinos I, Gruson D, Kabamba B, et al. Evaluation of two automated and three rapid
369 lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. *J Clin Virol*
370 **2020**; 128:104413. Available at:
371 <https://linkinghub.elsevier.com/retrieve/pii/S1386653220301554>.
- 372 15. Aj J, Kuivanen S, Kekäläinen E, et al. Performance of six SARS-CoV-2 immunoassays in
373 comparison with microneutralisation. *medRxiv* **2020**; Available at:
374 <https://www.medrxiv.org/content/10.1101/2020.05.18.20101618v1.full.pdf>.
- 375 16. Paradiso AV, Summa S De, Loconsole D, et al. Clinical meanings of rapid serological
376 assay in patients tested for SARS-Co2 RT-PCR. *medRxiv* **2020**; :2020.04.03.20052183.
- 377 17. Pan Y, Li X, Yang G, et al. Serological immunochromatographic approach in diagnosis
378 with SARS-CoV-2 infected COVID-19 patients. *J Infect* **2020**;
- 379 18. Bond K, Nicholson S, Hoang T, Catton M, Howden B, Williamson D. Post-market
380 validation of three serological assays for COVID-19. 2020.
- 381 19. Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-CoV-2
382 serological assays. *medRxiv* **2020**; :2020.04.25.20074856.

- 383 20. Klein S, Pekosz A, Park H-S, et al. Sex, age, and hospitalization drive antibody responses
384 in a COVID-19 convalescent plasma donor population. medRxiv **2020**;
385 :2020.06.26.20139063. Available at:
386 <http://medrxiv.org/content/early/2020/06/28/2020.06.26.20139063.abstract>.
- 387 21. Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-CoV-2
388 serological assays. medRxiv **2020**; :2020.04.25.20074856. Available at:
389 <http://medrxiv.org/content/early/2020/05/17/2020.04.25.20074856.abstract>.
- 390 22. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the
391 prevention and treatment of COVID-19. *J Clin Invest* **2020**; 130:2757–2765.
- 392 23. Lou B, Li T, Zheng S, et al. Serology characteristics of SARS-CoV-2 infection since the
393 exposure and post symptoms onset. medRxiv **2020**; :2020.03.23.20041707. Available at:
394 <http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041707.abstract>.
- 395 24. Shen B, Zheng Y, Zhang X, et al. Clinical evaluation of a rapid colloidal gold
396 immunochromatography assay for SARS-Cov-2 IgM/IgG. *Am J Transl Res* **2020**;
397 12:1348–1354.
- 398 25. Lassaunière R, Frische A, Harboe ZB, et al. Evaluation of nine commercial SARS-CoV-2
399 immunoassays. medRxiv **2020**; :2020.04.09.20056325.
- 400 26. Hardick J, Sadiq S, Perelstein E, Peterson S, Rothman R, Gaydos CA. A case-control
401 study evaluating RT-PCR/ESI-MS technology compared to direct fluorescent antibody
402 and xTAG RVP PCR. *Diagn Microbiol Infect Dis* **2014**; 79:187–189.
- 403 27. Xu GJ, Kula T, Xu Q, et al. Comprehensive serological profiling of human populations

- 404 using a synthetic human virome. *Science* (80-) **2015**; 348.
- 405 28. Mohan D, Wansley DL, Sie BM, et al. PhIP-Seq characterization of serum antibodies
406 using oligonucleotide-encoded peptidomes. *Nat Protoc* **2018**; 13:1958–1978.
- 407 29. Garcia FP, Perez Tanoira R, Romanyk Cabrera JP, Arroyo Serrano T, Gomez Herruz P,
408 Cuadros Gonzalez J. Rapid diagnosis of SARS-CoV-2 infection by detecting IgG and IgM
409 antibodies with an immunochromatographic device: a prospective single-center study.
410 *medRxiv* **2020**; :2020.04.11.20062158. Available at:
411 <http://medrxiv.org/content/early/2020/04/24/2020.04.11.20062158.abstract>.
- 412 30. Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa
413 Clara County, California. *medRxiv* **2020**; :2020.04.14.20062463. Available at:
414 [https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1?fbclid=IwAR3NrK8o](https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1?fbclid=IwAR3NrK8oRFFOVulmb1_4hMJpOUvKUgC6MuS7vi7jPvNyy2xeTPIZoaYmlxA)
415 [RFFOVulmb1_4hMJpOUvKUgC6MuS7vi7jPvNyy2xeTPIZoaYmlxA](https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1?fbclid=IwAR3NrK8oRFFOVulmb1_4hMJpOUvKUgC6MuS7vi7jPvNyy2xeTPIZoaYmlxA).
- 416 31. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody tests in
417 detecting SARS-CoV-2 infection: A meta-analysis. *Diagnostics* **2020**;
418 10:2020.04.22.20074914. Available at:
419 <http://medrxiv.org/content/early/2020/04/25/2020.04.22.20074914.abstract>.
- 420 32. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *Jama*
421 **2020**; 2019:2019–2021. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/32374370>.
- 422 33. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel
423 coronavirus disease 2019. *Clin Infect Dis* **2020**; :1–22.
- 424 34. Xiang F, Wang X, He X, et al. Antibody Detection and Dynamic Characteristics in

- 425 Patients with COVID-19. *Clin Infect Dis* **2020**; :1–23.
- 426 35. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first report.
427 *J Infect* **2020**; :10–11.
- 428 36. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative
429 Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by
430 Time Since Exposure. *Ann Intern Med* **2020**;
- 431

Table 1. Sample set used for the evaluation of SARS-CoV-2 antibody-based POCTs.

Sample Set	Number of patients	Description
Convalescent	40	'Gold standard' positives; known to be RT-PCR positive >28 days post-onset of symptoms.
Pre-pandemic	60	Pre-pandemic era 'gold standard' negative samples
Longitudinal	47	Longitudinal samples (N=272) of RT-PCR positive for SARS-CoV-2 infection beginning from 0 to 20 days post-onset of symptoms.

Figure Legends

Figure 1. Representative examples of results obtained with the POCT antibody lateral flow assays. A result is considered invalid if control band is not visible regardless of observing the IgM and/or IgG bands. A negative result is determined when only the control band is visible, while for positive results there are three probable outcomes along with the observation of a control band: IgM band only, IgG band only, or IgM and IgG bands.

Figure 2. Analytical sensitivity and specificity towards IgM and IgG for the evaluated SARS-CoV-2 antibody-based assays. The boxes represent the lower and upper 95% confidence interval, and the line inside the boxes indicate the determined values for each assay.

Figure 3. Comparison of fifteen evaluated POCT LFA and two ELISA-based assay results obtained by testing the designated negative or positive plasma sample. A) Results obtained from evaluating pre-pandemic (negative) and convalescent (positive) plasma. Any detection of IgM, IgG, or both is shown as a positive result (blue color), whereas lack of detection is shown as a negative result (yellow color). Those marked as gray indicate an invalid result, while those marked as white represent missing data for comparison. B) Percent agreement (IgM or IgG) between each POCT lateral flow assays and ELISAs (in *italics*). Value represents the percentage agreement.

Figure 4. Longitudinal evaluation of analytical performance for four SARS-CoV-2 antibody-based POCTs and two ELISAs. The boxes represent the lower and upper 95% confidence interval, and the line inside the boxes indicate the determined values for each assay at each indicated time range.

Figure 1.




Figure 2.




Figure 3.




Figure 4.

